NCT04304755View on ClinicalTrials.gov

Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

January 24, 2024

Study Completion Date

January 24, 2024

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Zoledronic Acid 5 MG in 5 ML Injection

Zoledronic acid

DRUG

Placebos

NaCl 0.9%

Trial Locations (2)

0176

Spesialistsenteret Pilestredet Park, Oslo

0407

Oslo university hospital, Department of Ophthamology, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER

NCT04304755 - Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD) | Biotech Hunter | Biotech Hunter